Dr. Peter A. Forsyth, MD

Dr. Forsyth practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Forsyth's NPI, 1841582285, was assigned on May 4, 2011. Dr. Forsyth graduated from Michael G. DeGroote School of Medicine in 1987. Dr. Forsyth holds Florida license ME109550.

Dr. Forsyth's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Forsyth's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Forsyth to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Forsyth practices, 2 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Forsyth's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Forsyth is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Forsyth's licenses on file in 2 states: Florida and Connecticut.

Dmand AI lists cerebrovascular disease and epilepsy among the conditions Dr. Forsyth treats.

CMS data shows 79 Medicare services from Dr. Forsyth across 2 procedure codes in 2024, all of them office visits, for 76 Medicare patients. Medicare paid $5,527 for them.

CMS counts 76 Medicare patients who saw Dr. Forsyth in 2024. The largest group is 65 to 74, with 37 patients. 62% of them have high cholesterol, and 54% have high blood pressure. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Forsyth's median patient age at 58, with 59% women.

In 2024, Dr. Forsyth wrote 252 Medicare Part D claims for 35 patients. 85% of them were for generic drugs. CMS names the drug for 166 of them, across 8 drugs with 11 or more claims each, at $20,007 in total drug cost. In 2023, CMS named 96 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Forsyth for performance year 2024, reported as part of a group. Dr. Forsyth accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Forsyth as offering telehealth.

Dmand AI links 252 papers to Dr. Forsyth, published from 2004 to 2025. 2021 was the busiest year, with 14. The most frequent topics are Brain Neoplasms, Glioma and Melanoma. Dr. Forsyth has published most often in J Neurooncol. Dr. Forsyth's most frequent co-authors are Arnold Besohong Etame, MD, Kamran Ali Ahmed, MD and Solmaz Sahebjam, MD.

Dmand AI links Dr. Forsyth to 20 clinical trials, 7 of them phase 2 studies. 10 are still active or recruiting. Conditions studied include Brain Neoplasms, Meningeal Neoplasms and Central Nervous System Neoplasms. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 9.

CMS Open Payments shows 59 general payments to Dr. Forsyth from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 56% of the total. BTG International, Inc. paid the most, $6,187. It also lists 1 research payment totaling $940 in 2021.

Dr. Forsyth graduated from Michael G. DeGroote School of Medicine in 1987.

Dr. Forsyth is in network with 11 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 8. Check the plan with the practice before a visit.